|
Synonyms: hPD-1 mAb 7(1.2) [6] | INCMGA0012 | MGA012 | retifanlimab-dlwr | Zynyz®
retifanlimab is an approved drug (FDA (2023))
Compound class:
Antibody
Comment: Retifanlimab (MGA012) is a humanized IgG4 anti-PD-1 monoclonal antibody. It was developed by MacroGenics for anti-cancer potential. Retifanlimab blocks the interaction between PD-1 and its ligands PD-L1/2, and it acts as an immune checkpoint modulator.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Catenacci DV, Rosales M, Chung HC, H Yoon H, Shen L, Moehler M, Kang YK. (2021)
MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. Future Oncol, 17 (10): 1155-1164. [PMID:33263418] |
|
2. Farias JPF, Rangel da Silva MHC, Jácome AA. (2021)
Emerging and Experimental Agents for Anal Cancer: What is New?. J Exp Pharmacol, 13: 433-440. [PMID:33859504] |
|
3. Kang C. (2023)
Retifanlimab: First Approval. Drugs, 83 (8): 731-737. [PMID:37184754] |
|
4. Rao S, Anandappa G, Capdevila J, Dahan L, Evesque L, Kim S, Saunders MP, Gilbert DC, Jensen LH, Samalin E et al.. (2022)
A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). ESMO Open, 7 (4): 100529. [PMID:35816951] |
|
5. Rao S, Jones M, Bowman J, Tian C, Spano JP. (2022)
POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin-paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma. Front Oncol, 12: 935383. [PMID:36091159] |
|
6. Shah K, Smith DH, La Motte-Mohs R, Johnson LS, Moore PA, Bonvini E, Koenig S. (2017)
Pd-1-binding molecules and methods use thereof. Patent number: WO2017019846A1. Assignee: Macrogenics, Inc.. Priority date: 30/07/2015. Publication date: 02/02/2017. |
